IRIS Accounts Production v26.1.0.640 10209555 Board of Directors 31.12.25 1.1.25 31.12.25 31.12.25 a distributor of laboratory equipment and consumables with a broad and complete product portfolio. The group also offers a National and International laboratory equipment installation, service, and maintenance offering. This all allows the group to meet its customers demands through a tailored, flexible, and fast service. The groups' objective continues to be positioning itself as the supplier of choice in its key markets supplying the highest quality, best value products, service, and brands to its customer base. true true true false true true false false false false false false false false false false false false false false false false false false false false false true false Ordinary A 1.00000 Ordinary B 1.00000 Preference 0.010 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh102095552024-12-31102095552025-12-31102095552025-01-012025-12-31102095552023-12-31102095552024-01-012024-12-31102095552024-12-3110209555ns15:EnglandWales2025-01-012025-12-3110209555ns14:PoundSterling2025-01-012025-12-3110209555ns10:Director12025-01-012025-12-3110209555ns10:Consolidated2025-12-3110209555ns10:ConsolidatedGroupCompanyAccounts2025-01-012025-12-3110209555ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3110209555ns10:FRS102ns10:Consolidated2025-01-012025-12-3110209555ns10:Consolidatedns10:Audited2025-01-012025-12-3110209555ns10:LargeCompaniesRegimeForDirectorsReport2025-01-012025-12-3110209555ns10:LargeCompaniesRegimeForAccounts2025-01-012025-12-3110209555ns10:Consolidatedns10:LargeCompaniesRegimeForDirectorsReport2025-01-012025-12-3110209555ns10:Consolidatedns10:LargeCompaniesRegimeForAccounts2025-01-012025-12-3110209555ns10:FullAccounts2025-01-012025-12-3110209555ns5:Subsidiary12025-01-012025-12-3110209555ns5:Subsidiary22025-01-012025-12-3110209555ns5:Subsidiary32025-01-012025-12-3110209555ns5:Subsidiary42025-01-012025-12-3110209555ns5:Subsidiary52025-01-012025-12-3110209555ns5:Subsidiary62025-01-012025-12-3110209555ns5:Subsidiary72025-01-012025-12-3110209555ns5:Subsidiary82025-01-012025-12-3110209555ns5:Subsidiary92025-01-012025-12-3110209555ns5:Subsidiary102025-01-012025-12-3110209555ns5:Subsidiary112025-01-012025-12-3110209555ns5:Subsidiary122025-01-012025-12-3110209555ns5:Subsidiary132025-01-012025-12-3110209555ns5:Subsidiary142025-01-012025-12-3110209555ns5:Subsidiary152025-01-012025-12-3110209555ns5:Subsidiary172025-01-012025-12-3110209555ns5:Subsidiary182025-01-012025-12-3110209555ns5:Subsidiary192025-01-012025-12-311020955512025-01-012025-12-3110209555ns10:OrdinaryShareClass12025-01-012025-12-3110209555ns10:OrdinaryShareClass22025-01-012025-12-3110209555ns10:OrdinaryShareClass32025-01-012025-12-3110209555ns10:Consolidated2025-01-012025-12-3110209555ns10:Director22025-01-012025-12-3110209555ns10:Director32025-01-012025-12-3110209555ns10:Director42025-01-012025-12-3110209555ns10:CompanySecretary12025-01-012025-12-3110209555ns10:RegisteredOffice2025-01-012025-12-3110209555ns10:Consolidated2024-01-012024-12-3110209555ns5:CurrentFinancialInstruments2025-12-3110209555ns5:CurrentFinancialInstruments2024-12-3110209555ns5:Non-currentFinancialInstruments2025-12-3110209555ns5:Non-currentFinancialInstruments2024-12-3110209555ns5:ShareCapital2025-12-3110209555ns5:ShareCapital2024-12-3110209555ns5:SharePremium2025-12-3110209555ns5:SharePremium2024-12-3110209555ns5:RetainedEarningsAccumulatedLosses2025-12-3110209555ns5:RetainedEarningsAccumulatedLosses2024-12-3110209555ns5:ShareCapital2023-12-3110209555ns5:RetainedEarningsAccumulatedLosses2023-12-3110209555ns5:SharePremium2023-12-3110209555ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3110209555ns5:RetainedEarningsAccumulatedLosses2025-01-012025-12-311020955512025-01-012025-12-3110209555ns5:NetGoodwill2025-01-012025-12-3110209555ns5:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3110209555ns5:PatentsTrademarksLicencesConcessionsSimilar2025-01-012025-12-3110209555ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-012025-12-3110209555ns5:PlantMachinery2025-01-012025-12-3110209555ns5:FurnitureFittings2025-01-012025-12-3110209555ns5:MotorVehicles2025-01-012025-12-3110209555ns5:ComputerEquipment2025-01-012025-12-3110209555ns5:CostValuation2024-12-31102095551ns5:Subsidiary12025-01-012025-12-3110209555ns5:Subsidiary12025-12-3110209555ns5:Subsidiary12024-12-3110209555ns5:Subsidiary12024-01-012024-12-3110209555ns5:Subsidiary232025-01-012025-12-31102095554ns5:Subsidiary22025-01-012025-12-3110209555ns5:Subsidiary22025-12-3110209555ns5:Subsidiary22024-12-3110209555ns5:Subsidiary22024-01-012024-12-31102095555ns5:Subsidiary32025-01-012025-12-3110209555ns5:Subsidiary32025-12-3110209555ns5:Subsidiary32024-12-3110209555ns5:Subsidiary32024-01-012024-12-3110209555ns5:Subsidiary472025-01-012025-12-3110209555ns5:Subsidiary42025-12-3110209555ns5:Subsidiary42024-12-3110209555ns5:Subsidiary42024-01-012024-12-31102095559ns5:Subsidiary52025-01-012025-12-3110209555ns5:Subsidiary52025-12-3110209555ns5:Subsidiary52024-12-3110209555ns5:Subsidiary52024-01-012024-12-3110209555ns5:Subsidiary6112025-01-012025-12-3110209555ns5:Subsidiary62025-12-3110209555ns5:Subsidiary62024-12-3110209555ns5:Subsidiary62024-01-012024-12-311020955513ns5:Subsidiary72025-01-012025-12-3110209555ns5:Subsidiary72025-12-3110209555ns5:Subsidiary72024-12-3110209555ns5:Subsidiary72024-01-012024-12-3110209555ns5:Subsidiary8152025-01-012025-12-3110209555ns5:Subsidiary82025-12-3110209555ns5:Subsidiary82024-12-3110209555ns5:Subsidiary82024-01-012024-12-311020955517ns5:Subsidiary92025-01-012025-12-3110209555ns5:Subsidiary92025-12-3110209555ns5:Subsidiary92024-12-3110209555ns5:Subsidiary92024-01-012024-12-311020955519ns5:Subsidiary102025-01-012025-12-3110209555ns5:Subsidiary102025-12-3110209555ns5:Subsidiary102024-12-3110209555ns5:Subsidiary102024-01-012024-12-311020955521ns5:Subsidiary112025-01-012025-12-3110209555ns5:Subsidiary112025-12-3110209555ns5:Subsidiary112024-12-3110209555ns5:Subsidiary112024-01-012024-12-311020955523ns5:Subsidiary122025-01-012025-12-3110209555ns5:Subsidiary122025-12-3110209555ns5:Subsidiary122024-12-3110209555ns5:Subsidiary122024-01-012024-12-311020955525ns5:Subsidiary132025-01-012025-12-3110209555ns5:Subsidiary132025-12-3110209555ns5:Subsidiary132024-12-3110209555ns5:Subsidiary132024-01-012024-12-3110209555ns5:Subsidiary14272025-01-012025-12-3110209555ns5:Subsidiary142025-12-3110209555ns5:Subsidiary142024-12-3110209555ns5:Subsidiary142024-01-012024-12-3110209555ns5:Subsidiary15292025-01-012025-12-3110209555ns5:Subsidiary152025-12-3110209555ns5:Subsidiary152024-12-3110209555ns5:Subsidiary152024-01-012024-12-311020955532ns5:Subsidiary172025-01-012025-12-3110209555ns5:Subsidiary172025-12-3110209555ns5:Subsidiary18332025-01-012025-12-3110209555ns5:Subsidiary182025-12-311020955534ns5:Subsidiary192025-01-012025-12-3110209555342025-01-012025-12-3110209555ns5:Subsidiary192025-12-3110209555ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3110209555ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3110209555ns10:OrdinaryShareClass12025-12-3110209555ns10:OrdinaryShareClass22025-12-3110209555ns10:OrdinaryShareClass32025-12-3110209555ns5:RetainedEarningsAccumulatedLosses2024-12-3110209555ns5:SharePremium2024-12-31
REGISTERED NUMBER: 10209555 (England and Wales)














Group Strategic Report,

Report of the Directors and

Consolidated Financial Statements

for the Year Ended 31st December 2025

for

Scientific Laboratory Supplies Group Ltd

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)






Contents of the Consolidated Financial Statements
for the year ended 31st December 2025




Page

Company Information 1

Group Strategic Report 2

Report of the Directors 6

Energy and Carbon Report forming part of the Report of
the Directors

8

Report of the Independent Auditors 10

Consolidated Statement of Comprehensive Income 14

Consolidated Balance Sheet 15

Company Balance Sheet 16

Consolidated Statement of Changes in Equity 17

Company Statement of Changes in Equity 18

Consolidated Cash Flow Statement 19

Notes to the Consolidated Cash Flow Statement 20

Notes to the Consolidated Financial Statements 22


Scientific Laboratory Supplies Group Ltd

Company Information
for the year ended 31st December 2025







DIRECTORS: D. E. Wencker
I. A. Roulstone
J. J. R. Chapman
N. A. Bewell



SECRETARY: N. A. Bewell



REGISTERED OFFICE: Orchard House
The Square
Hessle
East Yorkshire
HU13 0AE



REGISTERED NUMBER: 10209555 (England and Wales)



AUDITORS: Sadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX



BANKERS: Barclays Bank plc
Humber & Lincolnshire Team
4th Floor
2 Humber Quays
Hull
HU1 2BN

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Group Strategic Report
for the year ended 31st December 2025

The directors present their strategic report of the company and the group for the year ended 31st December 2025.

REVIEW OF BUSINESS
The group is principally a distributor of laboratory equipment and consumables with a broad product portfolio. The group also offers national and international laboratory equipment installation, service and maintenance. This enables the group to meet customer demand through a tailored, flexible and fast service. The group's objective remains to position itself as the supplier of choice in its key markets by supplying high-quality, good-value products, service and brands to its customer base.

The key financial performance indicators used to monitor performance are turnover, gross profit percentage, Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and EBITDA percentage.

The key financial performance indicators for the last four years are as follows:

Year ended Year ended Year ended Year ended
31.12.2025 31.12.2024 31.12.2023 31.12.2022
£ £ £ £
Turnover 118.9M 115.0M 111.9M 99.4M
Gross Profit Margin 21.5% 21.7% 22.9% 22.1%
EBITDA 5.8M 5.6M 6.9M 5.5M
EBITDA % 4.9% 4.9% 6.2% 5.6%

The Directors are pleased with the performance of the group during the year.

In line with its long-term strategic plan, the group has continued to assess the market and seek opportunities to accelerate growth and address gaps in market and portfolio coverage. This has resulted in targeted investment within existing group companies and the completion of two further acquisitions into the group during 2025.

The group continues to seek new markets, new supplier relationships and additional product lines, allowing it to approach the market with a strong portfolio and presence. The group is committed to serving the market with a broad, complete and market-leading product and service portfolio alongside first-class, customer-oriented service. While the market has seen increased competition in an uncertain wider macroeconomic environment, the Board believes that the sector in which it operates, together with the group's longer-term strategic plan, will continue to provide opportunities for future growth and development.

The Directors remain focused on the importance of the group's employees. The enhancement of staff satisfaction, engagement, morale, diversity, wellbeing and equal opportunities, together with competitive pay and benefits, is key to the group's values and strategic plan. The group will continue to invest in its people while managing the increased cost of employment levied on business through Central Government policy.

Overall EBITDA improved compared with 2024 to £5.8M (4.9% of turnover). Despite challenging market conditions and increased cost and margin pressures, the group continued to grow turnover and improve total EBITDA. The Directors consider the group to be well positioned to deliver further sales and EBITDA growth in line with its long-term strategic goals.

Overall, the group was in a healthy financial position at the close of 2025. The group had cash reserves of £9.8M at the year-end balance sheet date and very little external borrowing. The group continues to hold sufficient cash reserves to allow it to trade effectively.

These results are reflected in a healthy balance sheet, with net assets of £31.9M (2024: £30.2M).


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Group Strategic Report
for the year ended 31st December 2025

PRINCIPAL RISKS AND UNCERTAINTIES
The Board of Directors is ultimately responsible for risk management and continues to develop policies and procedures that reflect the nature and scale of the business. These are designed to identify, manage, and mitigate risk. The Board has identified the following areas of risk to the business and strategies to manage and mitigate the risk.

Financial instrument risk
The group has an established risk and financial management framework whose primary objectives are to protect the group and its companies from events that hinder the group's performance objectives. The objectives aim to ensure sufficient working capital exists and monitor the management of risk at a business unit level. More specifically, the group has implemented policies that require appropriate credit checks on potential customers before sales are made. The amount of exposure to any individual party is subject to a limit which is continually reviewed by the Directors and Senior Managers. In addition, the group reviews its trade receivables analysis monthly, and actions plans for overdue account are put in place when identified. In all instances review processes are in place with actions, if necessary, to ensure that the risks posed in these areas are mitigated fully. Risks are assessed through operational review meetings, KPI's and support from external advisors. When needed, changes are made to internal processes and controls are applied to address any changes in this area.

Competitive Risks
The group operates in a competitive market and faces the ongoing challenge of a changing competitive landscape along with pricing pressure across most of its markets. The group has an effective, coherent, and consistent strategy to respond to its competitors and market, coupled with a flexible and service orientated operating model to counter these risks.

Price Risk
The group is exposed to fluctuations in supplier pricing mainly through changes in commodity prices. The group manages this risk through maintaining adequate inventory levels and continuously monitoring supplier pricing.

Credit Risk
Credit risk arises from cash and deposit balances held with banks as well as credit exposures to customers. Credit risks are managed through working with only approved banks that are regularly monitored for their credit worthiness. Credit exposures are managed by the group through implementing policies that require:

- appropriate credit checks to be performed on customers prior to sales being made
- collection of receivable balances within agreed payment terms
- regular review on the credit status of existing customers

Liquidity Risk
The group manages liquidity risk via credit facilities and long-term debt. The group has a strong liquidity ratio, and additionally has sufficient facilities in place with both its bankers and through ultimate parent facilities to mitigate any negative cash flow risks.

Foreign exchange risk
The group has exposure to foreign currency transactions but does not consider currency movements to be a risk factor in relation to the business. The group operates foreign currency bank accounts to offset currency receipts and payment and when necessary, enters currency hedge contracts to control its exposures in this area.

Interest Rate and Cash Flow Risk
The group has access to interest bearing facilities and manages its risk to variable rate changes by closely managing cash generation by its operations and the application of robust cash collection targets throughout the company.


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Group Strategic Report
for the year ended 31st December 2025

SECTION 172(1) STATEMENT
Statement by the Directors in performance of their statutory duties in accordance with S172(1) of the Companies Act 2006

The Board of Scientific Laboratory Supplies Group Limited considers, both individually and collectively, the matters set out in section 172(1) of the Companies Act 2006 when making decisions.

The Directors recognise that the long-term success of the group depends on maintaining effective relationships with key stakeholders (including employees, customers, suppliers, banking partners, shareholders and the communities in which we operate) and on maintaining high standards of business conduct. The Board seeks to understand stakeholder views through regular management reporting, operational reviews and direct engagement, and takes these into account alongside the company's purpose, strategy, risk appetite and available resources.

During the year, the Board's principal areas of focus included progressing the group's long-term strategic plan (including the integration into the group of two acquisitions completed in 2025), investment in systems and capabilities to support future growth, and continued oversight of the group's financial strength, risk management and operational resilience.

Consequences of long-term decisions
The Directors are aware of the long-term implications of the strategic decisions they make and consider the impact of those decisions on the business, its employees and other stakeholders.

During the year, the Directors and the leadership teams of the subsidiary undertakings reviewed and refreshed the group's five-year strategic plan, together with its vision, mission and values. The strategy is structured around five key pillars which the Board considers critical to achieving long-term objectives. In reviewing and implementing the strategy, the Directors balance the need to deliver continued growth with the group's capabilities and infrastructure. More detailed plans and objectives for the coming year are incorporated into the annual budgets of the group's trading companies.

Employees
The Directors recognise the group's workforce as a key asset and consider employee engagement, wellbeing, development, diversity and inclusion when making decisions. Employees are offered competitive pay and benefits appropriate to their role, and the group undertakes an annual review of its benefits package. During the year, employees were involved in an engagement scheme to share feedback on company matters, including leadership, operations, wellbeing initiatives, incentive schemes, pay and conditions, and general business improvement. Feedback is reviewed by management and informs prioritisation of initiatives and investment.

Customers
The Directors recognise customer loyalty as invaluable and that meeting customer needs is central to the continuing success of the group. The group aims to deliver high levels of service and to identify solutions that support customers' requirements. Customer feedback is reviewed and used to improve service, relationships and communication.

Suppliers and Partners
The Directors recognise and value the role that suppliers and business partners play in the group's success. The group seeks to build long-term relationships, working collaboratively to maximise mutual value and to support the needs of customers. The Directors consider the importance of maintaining a strong reputation for fair dealing and high standards of business conduct in these relationships.

Communities
The Directors recognise the group's responsibility to be a supportive and engaged member of the communities in which it operates. The group supports several charities through fundraising and awareness activities and encourages employee involvement. The Directors also consider the impact of the group's operations on the environment and, where appropriate, support initiatives that reduce waste and improve efficiency.


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Group Strategic Report
for the year ended 31st December 2025

FUTURE DEVELOPMENTS
The group remains committed to growing its market share, turnover and EBITDA in a sustainable way, aligned to its long-term strategic plan. The strategic plan includes initiatives to expand the business organically and, where appropriate, through further acquisitions, including entry into new geographical markets and expansion of customer, product and service portfolios.

ON BEHALF OF THE BOARD:





N. A. Bewell - Director


8th May 2026

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Report of the Directors
for the year ended 31st December 2025

The directors present their report with the financial statements of the company and the group for the year ended 31st December 2025.

DIVIDENDS
No dividends will be distributed for the year ended 31st December 2025.

FUTURE DEVELOPMENTS
Details of the company's future developments have been provided in the strategic report.

EVENTS SINCE THE END OF THE YEAR
Information relating to events since the end of the year is given in the notes to the financial statements.

DIRECTORS
The directors shown below have held office during the whole of the period from 1st January 2025 to the date of this report.

D. E. Wencker
I. A. Roulstone
J. J. R. Chapman
N. A. Bewell

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and
explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Report of the Directors
for the year ended 31st December 2025


AUDITORS
The auditors, Sadofskys, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





N. A. Bewell - Director


8th May 2026

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Energy and Carbon Report
forming part of the Report of the Directors
for the year ended 31st December 2025


Scientific Laboratory Supplies Group Limited takes action to improve energy efficiency every year as part of its drive for improvement in both energy performance and in the delivery of its ISO14001 Management System.

Methodology
The methodology applied to the calculation of GHG emissions is the GHG Protocol Corporate Accounting and Reporting Standard. Conversion factors have been taken from the UK Government's Greenhouse gas reporting: conversion factors 2025 which are available on the Government's website at;

https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2025


Data has been collected from the following sources:

Data Type Scope 1 Data Source


Gas Consumption
Invoices from supplier supported by meter readings taken on the last day of the
month


Van Fleet Diesel Consumption
Fuel card monthly invoicing in litres and van mileage cross referenced with fuel
type


Company car consumption
Company car mileage claimed for business activity, cross referenced with fuel
type

Data Type Scope 2 Data Source


Electricity Consumption
Invoices from supplier supported by meter readings taken on the last day of the
month

Electricity production Primary data from solar production monitoring software

Data Type Scope 3 Data Source


Business travel
Employee-owned vehicle mileage claimed for business activity, cross referenced
with fuel type


















Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Energy and Carbon Report
forming part of the Report of the Directors
for the year ended 31st December 2025






Total energy consumption (Scope 1 and Scope 2)
YE 31/12/25 YE 31/12/24
tCO2e tCO2e
Emissions resulting from activities for which the company is responsible
involving the combustion of gas (scope 1)

4.13

55.85
Emissions resulting from activities for which the company is responsible for
the combustion of fuel for the purpose of transport (scope 1)

278.85

215.86
Emissions resulting from activities for which the company is responsible for
the combustion of other fuels (scope 1)

28.1

48.00
Emissions resulting from the purchase of electricity by the company for its
own use (Scope 2, market-based)

8.73

19.64
Emissions resulting from the purchase of electricity by the company for its
own use (Scope 2, Location-based)

85.29

55.84
Emissions resulting from business travel in rental or employee-owned
vehicles where the company is responsible for purchasing the fuel (Scope 3,
Cat. 7 subset)


95.67


62.13
Total emissions (Scope 1 and Scope 2) Market based 319.81 339.35
Total emissions (Scope 1, 3, and subset of Scope 3) Market based 415.48 401.48
Intensity Ratio emissions per £million of turnover 3.49:1 3.49:1

During the year, the Group's largest company completed its first full year in the new National Distribution Centre (NDC), a BREAAM "Excellent" facility. The centre operates entirely on electricity, with no gas consumption. Additionally, 45% of the total electricity consumption in the facility is self-generated.

The remaining group companies have made transitions from natural gas to biogas. Due to this, emissions from gas combustion have decreased by 93%.

We are continuously investigating energy efficiency opportunities to reduce our overall consumption, such as through heating control systems.

Transport efficiency measures are in place to ensure optimal fuel consumption, alongside the efforts to transition company vehicles towards hybrid and electric.

Report of the Independent Auditors to the Members of
forming part of the Report of the Directors
Scientific Laboratory Supplies Group Ltd

Opinion
We have audited the financial statements of Scientific Laboratory Supplies Group Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 31st December 2025 which comprise the Consolidated Statement of Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31st December 2025 and of the group's profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report of the Independent Auditors to the Members of
forming part of the Report of the Directors
Scientific Laboratory Supplies Group Ltd


Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
forming part of the Report of the Directors
Scientific Laboratory Supplies Group Ltd


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management, and from our commercial knowledge and experience of a holding company.
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, UK tax legislation, and data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:
- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:
- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC, relevant regulators, and the company's legal advisors.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.


Report of the Independent Auditors to the Members of
forming part of the Report of the Directors
Scientific Laboratory Supplies Group Ltd

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Alan Brocklehurst (Senior Statutory Auditor)
for and on behalf of Sadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX

8th May 2026

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Consolidated
Statement of Comprehensive
Income
for the year ended 31st December 2025

2025 2024
Notes £    £    £    £   

TURNOVER 118,903,624 115,060,743

Cost of sales 93,384,564 90,116,276
GROSS PROFIT 25,519,060 24,944,467

Distribution costs 10,253,840 10,075,005
Administrative expenses 12,880,770 12,408,494
23,134,610 22,483,499
2,384,450 2,460,968

Other operating income 286,933 221,421
OPERATING PROFIT 4 2,671,383 2,682,389

Interest receivable and similar income 60,532 62,443
2,731,915 2,744,832

Interest payable and similar expenses 7 341,532 337,014
PROFIT BEFORE TAXATION 2,390,383 2,407,818

Tax on profit 8 805,653 984,264
PROFIT FOR THE FINANCIAL YEAR 1,584,730 1,423,554

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

1,584,730

1,423,554

Profit attributable to:
Owners of the parent 1,549,438 1,380,006
Non-controlling interests 35,292 43,548
1,584,730 1,423,554

Total comprehensive income attributable to:
Owners of the parent 1,584,730 1,423,554

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Consolidated Balance Sheet
31st December 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 18,976,155 20,389,120
Tangible assets 11 5,381,911 5,578,108
Investments 12 - -
24,358,066 25,967,228

CURRENT ASSETS
Stocks 13 8,163,774 8,068,408
Debtors 14 17,444,460 16,474,244
Cash at bank and in hand 9,759,702 7,595,715
35,367,936 32,138,367
CREDITORS
Amounts falling due within one year 15 21,466,457 20,988,049
NET CURRENT ASSETS 13,901,479 11,150,318
TOTAL ASSETS LESS CURRENT
LIABILITIES

38,259,545

37,117,546

CREDITORS
Amounts falling due after more than one year 16 (5,299,208 ) (5,714,683 )

PROVISIONS FOR LIABILITIES 20 (1,049,876 ) (1,077,132 )
NET ASSETS 31,910,461 30,325,731

CAPITAL AND RESERVES
Called up share capital 21 188,981 188,981
Share premium 22 14,805,019 14,805,019
Retained earnings 22 17,180,106 15,630,668
SHAREHOLDERS' FUNDS 32,174,106 30,624,668

NON-CONTROLLING INTERESTS 23 (263,645 ) (298,937 )
TOTAL EQUITY 31,910,461 30,325,731

The financial statements were approved by the Board of Directors and authorised for issue on 8th May 2026 and were signed on its behalf by:



N. A. Bewell - Director


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Company Balance Sheet
31st December 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 - -
Tangible assets 11 - -
Investments 12 20,575,829 20,575,829
20,575,829 20,575,829

CURRENT ASSETS
Debtors 14 240,000 240,000
Cash at bank 24,252 5,352
264,252 245,352
CREDITORS
Amounts falling due within one year 15 2,411,934 2,320,071
NET CURRENT LIABILITIES (2,147,682 ) (2,074,719 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

18,428,147

18,501,110

CREDITORS
Amounts falling due after more than one year 16 903,490 903,490
NET ASSETS 17,524,657 17,597,620

CAPITAL AND RESERVES
Called up share capital 21 188,981 188,981
Share premium 22 14,805,019 14,805,019
Retained earnings 22 2,530,657 2,603,620
SHAREHOLDERS' FUNDS 17,524,657 17,597,620

Company's loss for the financial year (72,963 ) (80,984 )

The financial statements were approved by the Board of Directors and authorised for issue on 8th May 2026 and were signed on its behalf by:





N. A. Bewell - Director


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Consolidated Statement of Changes in Equity
for the year ended 31st December 2025

Called up
share Retained Share
capital earnings premium
£    £    £   
Balance at 1st January 2024 188,981 14,250,662 14,805,019

Changes in equity
Total comprehensive income - 1,380,006 -
188,981 15,630,668 14,805,019
Non-controlling interest arising on
business combination

-

-

-
Balance at 31st December 2024 188,981 15,630,668 14,805,019

Changes in equity
Total comprehensive income - 1,549,438 -
188,981 17,180,106 14,805,019
Non-controlling interest arising on
business combination

-

-

-
Balance at 31st December 2025 188,981 17,180,106 14,805,019
Non-controlling Total
Total interests equity
£    £    £   
Balance at 1st January 2024 29,244,662 (342,485 ) 28,902,177

Changes in equity
Total comprehensive income 1,380,006 - 1,380,006
30,624,668 (342,485 ) 30,282,183
Non-controlling interest arising on
business combination

-

43,548

43,548
Balance at 31st December 2024 30,624,668 (298,937 ) 30,325,731

Changes in equity
Total comprehensive income 1,549,438 - 1,549,438
32,174,106 (298,937 ) 31,875,169
Non-controlling interest arising on
business combination

-

35,292

35,292
Balance at 31st December 2025 32,174,106 (263,645 ) 31,910,461

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Company Statement of Changes in Equity
for the year ended 31st December 2025

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1st January 2024 188,981 2,684,604 14,805,019 17,678,604

Changes in equity
Total comprehensive income - (80,984 ) - (80,984 )
Balance at 31st December 2024 188,981 2,603,620 14,805,019 17,597,620

Changes in equity
Total comprehensive income - (72,963 ) - (72,963 )
Balance at 31st December 2025 188,981 2,530,657 14,805,019 17,524,657

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Consolidated Cash Flow Statement
for the year ended 31st December 2025

2025 2024
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 5,584,139 3,725,498
Interest paid (305,026 ) (310,492 )
Interest element of hire purchase payments
paid

(36,506

)

(26,522

)
Tax paid (803,956 ) (1,046,774 )
Tax refund - 69,636
Tax in relation to prior years - (3,538 )
Net cash from operating activities 4,438,651 2,407,808

Cash flows from investing activities
Purchase of intangible fixed assets (590,275 ) (282,015 )
Purchase of tangible fixed assets (1,204,527 ) (1,692,240 )
Sale of tangible fixed assets 268,175 291,567
Investment in group company disposed - 2
Impairment in goodwill 7,552 150,000
Interest received 60,532 62,443
Net cash from investing activities (1,458,543 ) (1,470,243 )

Cash flows from financing activities
Loan repayments in period (5,823 ) (5,298 )
New hire purchase in year 245,251 462,827
Capital repayments in period (243,110 ) (170,919 )
Loan movement within group companies (812,439 ) (457,342 )
Net cash from financing activities (816,121 ) (170,732 )

Increase in cash and cash equivalents 2,163,987 766,833
Cash and cash equivalents at beginning of
year

2

7,595,715

6,828,882

Cash and cash equivalents at end of year 2 9,759,702 7,595,715

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Cash Flow Statement
for the year ended 31st December 2025

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2025 2024
£    £   
Profit before taxation 2,390,383 2,407,818
Depreciation charges 3,172,624 1,116,578
Profit on disposal of fixed assets (44,386 ) (150,533 )
Amortisation charges - 2,022,715
Finance costs 341,532 337,014
Finance income (60,532 ) (62,443 )
5,799,621 5,671,149
Increase in stocks (95,366 ) (883,324 )
(Increase)/decrease in trade and other debtors (982,795 ) 1,531,952
Increase/(decrease) in trade and other creditors 862,679 (2,594,279 )
Cash generated from operations 5,584,139 3,725,498

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31st December 2025
31/12/25 1/1/25
£    £   
Cash and cash equivalents 9,759,702 7,595,715
Year ended 31st December 2024
31/12/24 1/1/24
£    £   
Cash and cash equivalents 7,595,715 6,828,882


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Cash Flow Statement
for the year ended 31st December 2025

3. ANALYSIS OF CHANGES IN NET FUNDS

At 1/1/25 Cash flow At 31/12/25
£    £    £   
Net cash
Cash at bank and in hand 7,595,715 2,163,987 9,759,702
7,595,715 2,163,987 9,759,702
Debt
Finance leases (503,261 ) (2,141 ) (505,402 )
Debts falling due within 1 year (5,297 ) - (5,297 )
Debts falling due after 1 year (23,482 ) 5,823 (17,659 )
(532,040 ) 3,682 (528,358 )
Total 7,063,675 2,167,669 9,231,344

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements
for the year ended 31st December 2025

1. STATUTORY INFORMATION

Scientific Laboratory Supplies Group Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements.

Critical accounting judgements and key sources of estimation uncertainty
The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the actual related results. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying value of assets and liabilities within the next financial year are addressed below.

- Useful life and residual value
An estimation of the residual values and useful lives of tangible assets and intangible assets is required to be made at least annually. Judgement is required in estimating the useful lives of fixed asset categories. The residual value is the estimated amount that would be currently obtained from the disposal of the asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Turnover
Turnover is measured at the fair value of the consideration received, net of discounts and value added taxes. Turnover from the sale of goods is recognised when the risks and rewards of ownership of the goods have transferred to the buyer. This is usually at the point that the customer has acknowledged delivery for the goods.

Goodwill
Goodwill being the amount paid in connection with the acquisition of businesses, are being amortised over the useful life of either 10 or 20 years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Trade marks are being amortised evenly over their estimated useful life of twenty years.

Development costs are being amortised evenly over their estimated useful life of five years.

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Plant and machinery - 25% on reducing balance, 25% on cost, 20% on cost, 15% on reducing balance, 15% on cost, 10% on cost, 6.67% on cost, 15% to 25% on cost and straight line over 15 years
Fixtures and fittings - 25% on cost, 15% on reducing balance and 10% on cost
Motor vehicles - 25% on reducing balance and 25% on cost
Computer equipment - 33% on cost, 25% on cost, 20% on cost and 15% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The Directors are satisfied that the financial statements have been prepared on a going concern basis. The group in deploying its long term strategy believes it is well positioned to maintain and win further share in the expanding and diverse market segments in which the group operates.

Government grants
Government grants are recognised using the accruals model. Grants of a revenue nature are credited to income so as to match them with the expenditure to which they relate. Grants in respect of capital expenditure are credited to a deferred income account and are released to profit over the expected useful lives of the assets to which they relate.

A grant that becomes receivable as compensation for expenses or losses already incurred, or for the purpose of giving immediate financial support to the company with no future related costs, is credited to income in the period in which it becomes receivable.

Financial assets, financial liabilities and equity
Financial assets, other than investments and derivatives, are initially measured at transaction price (including transaction costs) and subsequently held at amortised cost, less any impairment.

Financial liabilities and equity are classified according to the substance of the financial instrument's contractual obligations, rather than the financial instrument's legal form. Financial liabilities, excluding convertible debt and derivatives, are initially measured at transaction price (after deducting transaction costs) and subsequently held at amortised cost.

3. EMPLOYEES AND DIRECTORS
2025 2024
£    £   
Wages and salaries 14,601,083 14,321,482
Social security costs 1,616,832 1,309,882
Other pension costs 728,012 681,655
16,945,927 16,313,019

The average number of employees during the year was as follows:
2025 2024

Selling and Distribution 263 261
Administration 102 107
365 368

The average number of employees by undertakings that were proportionately consolidated during the year was 365 (2024 - 368 ) .

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

3. EMPLOYEES AND DIRECTORS - continued

2025 2024
£    £   
Directors' remuneration 1,511,999 1,518,983
Directors' pension contributions to money purchase schemes 197,692 221,832

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 15 15

Information regarding the highest paid director is as follows:
2025 2024
£    £   
Emoluments etc 186,276 187,900
Pension contributions to money purchase schemes 15,695 25,466

4. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

2025 2024
£    £   
Hire of plant and machinery 9,238 15,529
Other operating leases 885,366 1,290,944
Depreciation - owned assets 979,399 956,580
Depreciation - assets on hire purchase contracts 197,536 159,998
Profit on disposal of fixed assets (44,386 ) (150,533 )
Goodwill amortisation 1,869,069 1,940,732
Development costs amortisation 126,619 81,983
Foreign exchange differences (196,740 ) (44,652 )

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

5. AUDITORS' REMUNERATION
2025 2024
£    £   
Fees payable to the company's auditors and their associates for the audit of
the company's financial statements

39,000

37,800
Fees payable to the company's auditors and their associates for other services to the group:
The auditing of accounts of any associate of the company 12,100 11,000
Total audit fees 51,100 48,800

Other non- audit services 25,000 24,500
Total non-audit fees 25,000 24,500
Total fees payable 76,100 73,300

6. EXCEPTIONAL ITEMS
2025 2024
£    £   
Exceptional items -
expenditure (23,980 ) (76,061 )

Exceptional items relate to dilapidation costs.

7. INTEREST PAYABLE AND SIMILAR EXPENSES
2025 2024
£    £   
Bank loan interest 234 799
Interest on corporation tax 13,534 8,845
Other loan interest 291,258 300,848
Hire purchase interest 36,506 26,522
341,532 337,014

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

8. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2025 2024
£    £   
Current tax:
UK corporation tax 840,585 932,375
Taxation re prior year - 3,538
Total current tax 840,585 935,913

Deferred taxation (34,932 ) 48,351
Tax on profit 805,653 984,264

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2025 2024
£    £   
Profit before tax 2,390,383 2,407,818
Profit multiplied by the standard rate of corporation tax in the UK of 25 %
(2024 - 25 %)

597,596

601,955

Effects of:
Expenses not deductible for tax purposes 135 -
Losses carried forward 7,662 -
Losses brought forward utilised (26,748 ) (32,025 )
Amortisation of goodwill/impairment of intangibles 469,156 489,684
Taxation re prior year 15,786 72,949
charge
Overseas profits taxed overseas/different rates (97,665 ) (148,299 )
charge
Depreciation on non-qualifying assets 7,677 -
Expenditure previously disallowed now allowable (167,946 ) -
Total tax charge 805,653 984,264

9. INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME

As permitted by Section 408 of the Companies Act 2006, the Statement of Comprehensive Income of the parent company is not presented as part of these financial statements.


Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

10. INTANGIBLE FIXED ASSETS

Group
Trade Development
Goodwill marks costs Totals
£    £    £    £   
COST
At 1st January 2025 31,566,547 3,064 553,289 32,122,900
Additions 326,954 - 263,321 590,275
Impairments (7,552 ) - - (7,552 )
At 31st December 2025 31,885,949 3,064 816,610 32,705,623
AMORTISATION
At 1st January 2025 11,628,621 - 105,159 11,733,780
Amortisation for year 1,869,069 - 126,619 1,995,688
At 31st December 2025 13,497,690 - 231,778 13,729,468
NET BOOK VALUE
At 31st December 2025 18,388,259 3,064 584,832 18,976,155
At 31st December 2024 19,937,926 3,064 448,130 20,389,120

11. TANGIBLE FIXED ASSETS

Group
Fixtures
Long Plant and and
leasehold machinery fittings
£    £    £   
COST
At 1st January 2025 16,346 3,687,373 142,695
Additions - 248,213 97,706
Disposals - (67,706 ) (33,873 )
At 31st December 2025 16,346 3,867,880 206,528
DEPRECIATION
At 1st January 2025 8,721 328,030 37,087
Charge for year - 330,174 46,115
Eliminated on disposal - (59,253 ) (9,612 )
At 31st December 2025 8,721 598,951 73,590
NET BOOK VALUE
At 31st December 2025 7,625 3,268,929 132,938
At 31st December 2024 7,625 3,359,343 105,608

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

11. TANGIBLE FIXED ASSETS - continued

Group

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1st January 2025 1,609,826 2,591,049 8,047,289
Additions 586,059 272,549 1,204,527
Disposals (464,187 ) - (565,766 )
At 31st December 2025 1,731,698 2,863,598 8,686,050
DEPRECIATION
At 1st January 2025 511,946 1,583,397 2,469,181
Charge for year 403,218 397,428 1,176,935
Eliminated on disposal (273,112 ) - (341,977 )
At 31st December 2025 642,052 1,980,825 3,304,139
NET BOOK VALUE
At 31st December 2025 1,089,646 882,773 5,381,911
At 31st December 2024 1,097,880 1,007,652 5,578,108

The net book value of tangible fixed assets includes £ 651,501 (2024 - £ 635,982 ) in respect of assets held under hire purchase contracts.

12. FIXED ASSET INVESTMENTS

Company
Shares in
group
undertakings
£   
COST
At 1st January 2025
and 31st December 2025 20,575,829
NET BOOK VALUE
At 31st December 2025 20,575,829
At 31st December 2024 20,575,829

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

SLS Group Limited
Registered office: Orchard House, The Square, Hessle, HU13 0AE
Nature of business: Holding company
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 9,380,360 6,253,986
Profit for the year 3,126,374 1,527,638

Scientific Laboratory Supplies Limited
Registered office: Orchard House, The Square, Hessle, HU13 0AE
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
Preference 100.00
2025 2024
£    £   
Aggregate capital and reserves 16,679,704 16,497,704
Profit for the year 182,000 533,641

Analab Analytical Laboratory Supplies Limited
Registered office: Unit 2 Rathdown Close, Lissue Industrial Estate West, Moira Road, Lisburn, BT28 2RB
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 9,397 9,272
Profit for the year 125 2,347

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

Gem Scientific (2014) Limited
Registered office: Orchard House, The Square, Hessle, HU13 0AE
Nature of business: Holding company
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves (26,640 ) (426,615 )
Profit for the year 399,975 449,909

Gem Scientific Limited
Registered office: Unit 301, Batley Enterprise Centre, 513 Bradford Road, Batley WF17 8LL
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 2,529,565 2,478,369
Profit for the year 451,196 489,345

Northern Balance Ltd
Registered office: Unit 3 Bamburgh Court, First Avenue, Team Valley Trading Estate, Gateshead NE11 0TX
Nature of business: Supply and install of weighing equipment
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 691,842 777,761
Loss for the year (85,918 ) (12,902 )

Sparks Lab Supplies Limited
Registered office: Unit 4 Block K, Greenogue Business Park, Grants Road, Rathcoole, Dublin
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 252,488 1,034,098
Profit/(loss) for the year 3,593 (80,544 )

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

Scientific Laboratory Supplies (Ireland) Limited
Registered office: Charter House, 5 Pembroke Row, Dublin 2, Ireland.
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 2,883,887 2,131,784
Profit for the year 1,729,329 1,150,846

Aurora Scientific Limited
Registered office: Unit 2 Gypsy Lane, Keymsham, Bristol BS21 2ED
Nature of business: Supplier of specialised sampling equipment
%
Class of shares: holding
Ordinary 65.00
2025 2024
£    £   
Aggregate capital and reserves (373,817 ) (474,651 )
Profit for the year 100,843 124,423

SLS Scientific Laboratory Supplies (Kenya) Limited
Registered office: P.O. Box 40111, Nairobi, Kenya
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves (39,667 ) (181,226 )
Profit for the year 141,727 28,955

Flow Group Holdings Limited
Registered office: Orchard House, The Square, Hessle, HU13 0AE
Nature of business: Holding company
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 4,615,475 4,615,580
Profit/(loss) for the year 999,475 (340,069 )

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

Wolf Laboratories Limited
Registered office: Colenso House, 1 Deans Lane, Pocklington, East Riding of Yorkshire, YO42 2PX
Nature of business: Distributor of laboratory equipment and consumables
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 2,341,311 2,317,796
Profit for the year 598,515 69,122

SCBS Holdings Limited
Registered office: 1 Brewster Square, Brucefield Industrial Estate, Livingston, Scotland, EH54 9BJ
Nature of business: Holding company
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 540,288 540,288
Profit for the year 1,050,000 460,000

The above investment was acquired on 11th January 2023.

C & M Scientific Limited
Registered office: 1 Brewster Square, Brucefield Industrial Estate, Livingston, Scotland, EH54 9BJ
Nature of business: Laboratory equipment servicing
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 2,003,192 1,972,813
Profit for the year 980,379 27,521

The above investment was acquired on 11th January 2023.

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

Biostore UK Ltd
Registered office: 1 Brewster Square, Brucefield Industrial Estate, Livingston, Scotland, EH54 9BJ
Nature of business: Storage of scientific samples
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 188,446 248,413
Profit/(loss) for the year 40,033 (62,128 )

The above investment was acquired on 11th January 2023.

Labserve Limited
Registered office: Orchard House, The Square, Hessle, HU13 0AE
Nature of business: Dormant
%
Class of shares: holding
Ordinary 100.00
2025
£   
Aggregate capital and reserves 1,000

Hilton Instruments Limited
Registered office: Howe Moss Avenue, Kirkhill Industrial Estate, Dyce, Aberdeen AB21 0GP
Nature of business: Distributor of laboratory equipment
%
Class of shares: holding
Ordinary 100.00
2025
£   
Aggregate capital and reserves 4,675,648
Loss for the year (30,563 )

The above investment was acquired by the group on 31st October 2025.

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

12. FIXED ASSET INVESTMENTS - continued

Culsalmond Property & Investment Company Limited
Registered office: Howe Moss Avenue, Dyce, Aberdeen, Scotland, AB21 0GP
Nature of business: Holding company
%
Class of shares: holding
Ordinary 100.00
2025
£   
Aggregate capital and reserves 96,213
Loss for the year (82 )

The above investment was acquired by the group on 31st October 2025.


All subsidiaries are consolidated in these financial statements, unless otherwise stated.

The shareholding in SLS Group Limited is held directly by the company. The other companies shown above are 100% subsidiaries of SLS Group Limited and therefore indirectly held by the company.

13. STOCKS

Group
2025 2024
£    £   
Stocks 1,629,373 1,262,813
Finished goods 6,534,401 6,805,595
8,163,774 8,068,408

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Trade debtors 16,393,184 15,496,088 - -
Amounts owed by group undertakings - - 240,000 240,000
Other debtors 67,185 10,874 - -
Taxation 102,127 51,564 - -
VAT 166,624 73,584 - -
Prepayments and accrued income 715,340 842,134 - -
17,444,460 16,474,244 240,000 240,000

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Bank loans and overdrafts (see note 17) 5,297 5,297 - -
Hire purchase contracts (see note 18) 213,951 181,836 - -
Trade creditors 15,658,904 14,962,652 - -
Amounts owed to group undertakings 991,025 1,216,286 2,339,121 2,239,121
Taxation 158,968 142,593 - -
Social security and other taxes 997,663 878,121 - -
Other creditors 608,133 478,712 - -
Accruals and deferred income 2,832,516 3,122,552 72,813 80,950
21,466,457 20,988,049 2,411,934 2,320,071

16. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Bank loans (see note 17) 17,659 23,482 - -
Hire purchase contracts (see note 18) 291,451 321,425 - -
Amounts owed to group undertakings 4,782,598 5,369,776 903,490 903,490
Other creditors 207,500 - - -
5,299,208 5,714,683 903,490 903,490

17. LOANS

An analysis of the maturity of loans is given below:

Group
2025 2024
£    £   
Amounts falling due within one year or on demand:
Bank loans 5,297 5,297
Amounts falling due between one and two years:
Bank loans - 1-2 years 17,659 23,482

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

18. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Hire purchase
contracts
2025 2024
£    £   
Net obligations repayable:
Within one year 213,951 181,836
Between one and five years 291,451 321,425
505,402 503,261

Group
Non-cancellable
operating leases
2025 2024
£    £   
Within one year 812,193 834,194
Between one and five years 2,320,241 2,373,763
In more than five years 1,446,369 1,771,824
4,578,803 4,979,781

19. SECURED DEBTS

The following secured debts are included within creditors:

Group
2025 2024
£    £   
Bank loans 22,956 28,779

The bank loan is secured by way of fixed and floating charge over the assets of the individual group company that has the borrowing.

20. PROVISIONS FOR LIABILITIES

Group
2025 2024
£    £   
Deferred taxation 1,049,876 1,077,132

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

20. PROVISIONS FOR LIABILITIES - continued

Group
Deferred
tax
£   
Balance at 1st January 2025 1,077,132
Credit to Statement of Comprehensive Income during year (34,932 )
Taxation on new acquisitions 7,676
Balance at 31st December 2025 1,049,876

21. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
150,000 Ordinary A £1 150,000 150,000
37,500 Ordinary B £1 37,500 37,500
14,806,500 Preference 0.01p 1,481 1,481
188,981 188,981

The Ordinary A and Ordinary B shares rank equally however they do constitute separate classes of shares.

Prior to an Exit, any dividend or distribution payable to the holders of the Ordinary Shares shall be applied as follows, 95% applies to Ordinary A and 5% to Ordinary B.

Preference Shares
The Preference Shareholders are entitled to be paid in respect of each financial year of the Company out of profits available for distribution from time to time resolved to be distributed a fixed cumulative preferential dividend at the annual rate of 5% on each Preference Share.

Preference shares confer the right to receive notice of but not attend or vote at a general meeting.

22. RESERVES

Group
Retained Share
earnings premium Totals
£    £    £   

At 1st January 2025 15,630,668 14,805,019 30,435,687
Profit for the year 1,549,438 1,549,438
At 31st December 2025 17,180,106 14,805,019 31,985,125

Scientific Laboratory Supplies Group Ltd (Registered number: 10209555)

Notes to the Consolidated Financial Statements - continued
for the year ended 31st December 2025

22. RESERVES - continued

Company
Retained Share
earnings premium Totals
£    £    £   

At 1st January 2025 2,603,620 14,805,019 17,408,639
Deficit for the year (72,963 ) (72,963 )
At 31st December 2025 2,530,657 14,805,019 17,335,676


23. NON-CONTROLLING INTERESTS

Non-controlling interests relate to a 35% holding in Aurora Scientific Limited. Scientific Laboratory Supplies Group Ltd holds an indirect interest of 65% in this company.

24. POST BALANCE SHEET EVENTS

In February 2026 it was announced that the entire shareholding of the company and its subsidiary companies, will be sold by LBO France to Vivo Capital. The completion date is to be confirmed.

25. ULTIMATE PARENT AND CONTROLLING PARTY

The ultimate controlling party is LBO France, a company registered in France (RCS Strasbourg Reg. No. 418354502). The immediate parent company is Dominique Dutscher, a company registered in France (RCS Strasbourg Reg. No. 325204725).

The parent of the largest group for which consolidated financial statements are drawn up is Dutscher Holding. Copies of the consolidated accounts can be obtained from 2C, Rue De Bruxelles, 67170, Bernolsheim, France.

Dutscher Holding SAS (incorporated in France) is regarded by the directors as being the company's ultimate parent company (RCS Strasbourg Reg. No. 882634660).